专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017081066A1 IMMUNOASSEMBLIN (IA) PROTEIN COMPLEXES 审中-公开
标题翻译：免疫组化（IA）蛋白复合物
公开(公告)号：WO2017081066A1
公开(公告)日：2017-05-18
申请号：PCT/EP2016/077098
申请日：2016-11-09
申请人： FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V. , RHEINISCH-WESTFÄLISCHE TECHNISCHE HOCHSCHULE AACHEN
发明人： EDGÜ, Güven , SACK, Markus , BEISS, Veronique , BOES, Alexander , SPIEGEL, Holger , REIMANN, Andreas , FISCHER, Rainer
IPC分类号： C07K14/705 , C07K16/00 , C07K16/20 , C07K14/445
CPC分类号： C07K16/205 , A61K39/002 , A61K2039/505 , C07K14/445 , C07K2319/00 , C07K2319/30
摘要： The technology provided herein relates to a novel type of recombinant protein complexes, in particular of antibody-like recombinant fusion protein complexes, hereinafter referred to as immunoassemblins (IAs), suitable as animal and human vaccines comprising a plurality of antigens or antigen domains derived from proteins preferably, but not necessarily presented on the surface of a pathogen. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins and protein complexes; antibodies induced or generated by the use of said vaccines or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.
摘要翻译：本文提供的技术涉及适用作动物和人类疫苗的新型重组蛋白复合物，特别是抗体样重组融合蛋白复合物（以下称为免疫组织（IAs）），其包含衍生自蛋白质的多个抗原或抗原结构域优选地但不一定呈递在病原体的表面上。编码所述重组蛋白质的核酸分子，载体，含有该核酸的宿主细胞以及制备和生产这种蛋白质和蛋白质复合物的方法; 通过使用所述疫苗或编码所述融合蛋白的所述核酸分子诱导或产生的抗体，以及这些抗体或重组衍生物用于被动免疫疗法的用途。

2. 发明申请

WO2020074704A1 MEANS AND METHODS FOR DETECTING SOY ALLERGENS 审中-公开
公开(公告)号：WO2020074704A1
公开(公告)日：2020-04-16
申请号：PCT/EP2019/077598
申请日：2019-10-11
申请人： FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
发明人： HAVENITH, Heide , SPIEGEL, Holger , SCHILBERG, Stefan , UEBERHAM, Elke , LEHMANN, Jörg
IPC分类号： C07K16/16 , G01N33/02
摘要： The present invention relates to the field of antibodies and their application in food and feedstuff quality control. In particular, the invention relates to amethod for the manufacture of an antibody that specifically binds to soy Gly m 8 protein wherein said method comprises immunisingan animal with the purified soy Glym8 protein, wherein said soy Glym8 protein has been obtained by expressing soy Glym8 protein inplants, and preferably,tobacco plants andpurifying the soy Glym8 protein from saidplants and, preferably,tobacco plantsand obtaining an antibody from the animal which specifically bind to soy Gly m8 protein,, wherein the animal will be sacrificed.Moreover, the invention contemplates an antibody obtained by said method as well as the use of said antibody for detecting soy material in a food preparation or feedstuff preparation. Further, a method for detecting soy material in a food preparation or feedstuff preparation and a kit for carrying out said method are provided.

3. 发明申请

WO2016037916A1 THREE-COMPONENT-MULTISTAGE MALARIA VACCINE 审中-公开
标题翻译：三元组合疟原虫疫苗
公开(公告)号：WO2016037916A1
公开(公告)日：2016-03-17
申请号：PCT/EP2015/070044
申请日：2015-09-02
申请人： FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
发明人： SPIEGEL, Holger , BOES, Alexander , EDGÜ, Güven , BEISS, Veronique , SACK, Markus , REIMANN, Andreas , PROF. DR. FISCHER, Rainer
IPC分类号： A61K39/015 , C12N15/62 , A61K39/00
CPC分类号： A61K39/015 , A61K2039/575 , A61K2039/64 , A61K2039/70 , C07K14/445 , C07K16/205 , C07K2319/00 , C07K2319/40 , C12N15/62 , Y02A50/412
摘要： The technology provided herein relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite main stages. The proteins may be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors and host cells containing the nucleic acids and methods for preparation and producing such proteins are also disclosed, as well as antibodies induced or generated by the use of said malaria vaccines and the use of such antibodies or recombinant derivatives for passive immunotherapy.
摘要翻译：本文提供的技术涉及由不同重组蛋白组成的新型疟疾疫苗，特别是包含来自红血球前，血液和性寄生虫主要阶段的几种不同恶性疟原虫抗原的重组融合蛋白。蛋白质可以用于混合物疫苗制剂中以在人体中引发保护性免疫应答。还公开了编码所述重组蛋白，含有核酸的载体和宿主细胞的核酸分子以及用于制备和产生此类蛋白质的方法，以及通过使用所述疟疾疫苗诱导或产生的抗体以及使用此类抗体或重组体被动免疫治疗的衍生物。

4. 发明申请

WO2015144874A1 MULTI-COMPONENT-MULTISTAGE MALARIA VACCINES 审中-公开
标题翻译：多组分多元疟原虫疫苗
公开(公告)号：WO2015144874A1
公开(公告)日：2015-10-01
申请号：PCT/EP2015/056693
申请日：2015-03-27
申请人： FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
发明人： BOES, Alexander , SPIEGEL, Holger , EDGÜ, Güven , BEISS, Veronique , SACK, Markus , REIMANN, Andreas , FISCHER, Rainer
IPC分类号： A61K39/00 , C07K14/445
CPC分类号： A61K39/015 , A61K2039/575 , A61K2039/70 , C07K14/445 , C07K16/205 , C07K2319/00 , C07K2319/21 , G01N33/56905 , G01N2333/445 , Y02A50/412
摘要： The present disclosure relates to novel malaria vaccines composed of different recombinant proteins, in particular recombinant fusion proteins comprising several different Plasmodium falciparum antigens from the pre-erythrocytic, the blood, and the sexual parasite stages. The proteins and/or fusion proteins will be used in a mixture vaccine formulation to elicit protective immune responses in humans. Nucleic acid molecules encoding said recombinant proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such proteins; Antibodies induced or generated by the use of said malaria vaccines or said nucleic acid molecules encoding said proteins and/or fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy.
摘要翻译：本公开涉及由不同重组蛋白组成的新型疟疾疫苗，特别是包含来自红血球前，血液和性寄生虫阶段的几种不同的恶性疟原虫抗原的重组融合蛋白。蛋白质和/或融合蛋白将用于混合物疫苗制剂中以在人体中引发保护性免疫应答。编码所述重组蛋白质的核酸分子，载体，含有核酸的宿主细胞以及用于制备和产生此类蛋白质的方法; 通过使用所述疟疾疫苗或编码所述蛋白质和/或融合蛋白的所述核酸分子诱导或产生的抗体以及使用这种抗体或重组衍生物进行被动免疫治疗。

5. 发明申请

WO2017042282A1 SOYBEAN ALLERGY RELATED EPITOPES 审中-公开
标题翻译：大豆过敏相关抗生素
公开(公告)号：WO2017042282A1
公开(公告)日：2017-03-16
申请号：PCT/EP2016/071196
申请日：2016-09-08
申请人： FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
发明人： KERN, Karolin , SPIEGEL, Holger , HAVENITH, Heide , SZARDENINGS, Michael
IPC分类号： A61K38/16 , C07K14/415 , C07K16/16
CPC分类号： C07K14/415 , C07K16/16 , C07K2317/34
摘要： The invention relates to a compilation comprising at least five different peptides, each peptide comprising at least one sequence element corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1 - 354, wherein at least five different epitopes are represented. The invention further relates to an in vitro method for determining a patient's immune status to soybean allergens, to a method for detecting at least one soybean allergen in a substance and to a method for determining the allergenicity of a soybean variety. Additionally, the invention relates to a kit comprising at least one composition containing a compound comprising at least five different sequence elements each corresponding to an epitope selected from the group consisting of SEQ ID NO.: 1 - 354, wherein at least five different epitopes are represented. Furthermore, the invention relates to the use of a peptide comprising a sequence element corresponding to an epitope for providing a molecule binding to a protein or peptide comprising the epitope.
摘要翻译：本发明涉及包含至少五种不同肽的汇编，每个肽包含对应于选自SEQ ID NO：1至354的表位的至少一个序列元件，其中表示至少五个不同的表位。本发明还涉及用于确定患者对大豆过敏原的免疫状态的体外方法，用于检测物质中的至少一种大豆过敏原的方法以及用于测定大豆品种的变应原性的方法。另外，本发明涉及一种试剂盒，其包含至少一种含有至少五种不同序列元件的化合物的组合物，每种化合物对应于选自SEQ ID NO：1至354的表位，其中至少五个不同的表位是表示。此外，本发明涉及包含对应于表位的序列元件以提供与包含表位的蛋白质或肽结合的分子的肽的用途。

6. 发明申请

WO2014174054A1 NOVEL VACCINES AGAINST APICOMPLEXAN PATHOGENS 审中-公开
标题翻译：新的疫苗对APICOMPLEXAN病人
公开(公告)号：WO2014174054A1
公开(公告)日：2014-10-30
申请号：PCT/EP2014/058409
申请日：2014-04-24
申请人： FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
发明人： BOES, Alexander , SPIEGEL, Holger , GÜVEN, Edgü , BEISS, Veronique , SACK, Markus , REIMANN, Andreas , FISCHER, Rainer
IPC分类号： A61K39/002 , A61K39/015 , C12N15/62
CPC分类号： C07K14/445 , A61K39/002 , A61K39/015 , C07K2319/00 , C07K2319/40 , C12N15/62 , Y02A50/412
摘要： The technology provided herein generally relates to novel fusion proteins suitable as human and/or animal vaccines against parasites or pathogens of the phylum Apicomplexa. In particular, the present disclosure relates to novel fusion proteins as a basis for vaccines against Plasmodium parasites, including P. falciparum, P. vivax, P. malariae, P. ovale and P. knowlesi . Nucleic acid molecules encoding said fusion proteins, vectors, host cells containing the nucleic acids and methods for preparation and producing such fusion proteins; antibodies induced or generated by the use of said fusion proteins or said nucleic acid molecules encoding said fusion proteins and the use of such antibodies or recombinant derivatives for passive immunotherapy; methods for producing such fusion proteins; compositions and methods for using such fusion proteins for the prevention and treatment of malaria are also encompassed by the present disclosure.
摘要翻译：本文提供的技术通常涉及适用于针对Apicomplexa门的寄生虫或病原体的人和/或动物疫苗的新型融合蛋白。特别地，本公开涉及新颖的融合蛋白作为针对疟原虫寄生虫的疫苗的基础，包括恶性疟原虫，间日疟原虫，疟原虫，疟原虫和P.nowlesi。编码所述融合蛋白，载体，含有核酸的宿主细胞的核酸分子和用于制备和产生此类融合蛋白的方法; 通过使用所述融合蛋白或编码所述融合蛋白的所述核酸分子诱导或产生的抗体以及所述抗体或重组衍生物用于被动免疫治疗的用途; 生产这种融合蛋白的方法; 用于预防和治疗疟疾的这种融合蛋白的组合物和方法也包括在本公开中。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式